# CYTOKINETICS, INCORPORATED (CYTK) · Edgar & Edgarette company card

> Cytokinetics, Incorporated (CYTK) grew revenue 377% in FY2025 to $88 million, operating margin -695% against a -3.8% median for pharmaceutical preparations, equity -46.3% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1061983 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/CYTK) · [JSON](https://www.pops4.com/boards/company/CYTK.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $88M |
| Revenue growth, 1 year | 376.6% |
| Revenue growth per year | 5.7% |
| Operating margin | -695.4% (prior year -2902.7%) |
| Net margin | -891.6% |
| Operating cash flow | −$510M |
| Capital spending | $25M |
| Free cash flow | −$535M |
| Cash | $123M |
| Long-term debt | $288M |
| Total assets | $1.4B |
| Total equity | −$660M |
| Equity ÷ assets | -46.3% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -7.91 (distress zone)
- Piotroski F: 2 of 9 (weak)
- Health Harbor boat: Rotting at the dock · four or more warning signs · liabilities exceed assets (often from years of share buybacks, not always distress); slow and jumpy: growing slower than its size class, with revenue that swings more; operating cash flow was negative; operating loss: a margin of -695.4% in FY2025; revenue is hard to predict: its 80% range is ±51%
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $88.0M (FY2025), total debt $287.6M. Experience: revenue up 376.6% on the year, up 5.7% a year over 4 years; operating margin -695.4%, up from -2902.7%. Soundness: equity -46.3% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $138.3M and $426.5M next year (method v4.1: its own 4-year record of growth weighed at 50% against $50M–100M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $144.3M to $410.0M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -695.4% against a -3.8% median; growth 376.6% against 13.7%.

Range logged 2026-09-26, receipt 1224731e2a6745df, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2025-11-14 ([filing](https://www.sec.gov/Archives/edgar/data/1061983/000119312525282889/0001193125-25-282889-index.htm))

## Recent filings

- 8-K · filed 2026-08-28 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1061983/000119312526372456/0001193125-26-372456-index.htm)
- 8-K · filed 2026-08-13 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1061983/000119312526348060/0001193125-26-348060-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/1061983/000119312526338217/0001193125-26-338217-index.htm)
- 8-K · filed 2026-08-06 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1061983/000119312526338021/0001193125-26-338021-index.htm)
- 8-K · filed 2026-05-27 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1061983/000119312526241840/0001193125-26-241840-index.htm)
- 8-K · filed 2026-05-08 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1061983/000119312526214606/0001193125-26-214606-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001061983.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1061983

## Cite

POPS4, Edgar & Edgarette: CYTOKINETICS, INCORPORATED (CYTK) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/CYTK. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.